Advance pre-clinical development of CC6166 as a macrofilaricide candidate for filarial diseases
current phase of drug development
updated 1 Jun 2021
DNDi and partners employed a drug repurposing approach to find compounds that may be active against the microfilariae Onchocerca guttura and Onchocerca lienalis, with the aim of developing a drug candidate for filarial indications. Several potential candidates were identified through hit-to-lead and lead optimization programmes that screened compound libraries provided by pharmaceutical companies. DNDi provided biological resources, expertise, and the target product profile to select the best candidates. In 2019, one of these candidates, CC6166, was selected for further development by DNDi and Bristol-Myers Squibb (formerly Celgene), and in late 2020, DNDi absorbed the project in its entirety.
Get our latest news, personal stories, research articles, and job opportunities.